Eton Pharmaceuticals, Inc. (ETON)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$47.15-7.04%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
QuarterlyIQ Insights · ETON
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 35.1% |
| Our one-year growth estimate | diamond | 89.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 53.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 8 industry peers
ETON — COO transition
Dated 2026-08-04
Chief Operating Officer — Danka Radosavljevic: Ms. Radosavljevic was promoted to Chief Operating Officer from her previous role.
Why it matters: Eton raised its 2026 revenue goal after strong first-half sales. A miss would weaken that growth story.
Supportive ifFull-year 2026 revenue is more than $145 million.
Worry ifFull-year 2026 revenue is $145 million or less.
Why it matters: Full approval is needed before Eton's planned April 2027 launch. The FDA decision will test the timing of this new growth driver.
Supportive ifFDA approves the age 6-to-11 label change by the March 29, 2027 PDUFA date, clearing the planned April launch path.
Worry ifFDA does not approve the age 6-to-11 label change by March 29, 2027, or the April launch is delayed.
Why it matters: The study may widen the U.S. patient group from about 200 to 1,000. A delay or failed study would weaken that opportunity.
Watch forEton doses the first patients by the end of 2026 and later reports results that support a wider U.S. label.
Also watch forNo patients are dosed by year-end, or the study does not support a wider U.S. label.
Why it matters: The study compares ET-700 with GALZIN and placebo. Positive results may lead to a pivotal study in early 2027.
Watch forEton reports positive pilot results in the second half of 2026. It moves to a pivotal study in early 2027.
Also watch forThe pilot results are not positive, or Eton does not move to a pivotal study in early 2027.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$197 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $452 loss on $10,000 · 4.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,545 loss on $10,000 · 25.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The first-half margin moved from 67% in Q1 to 73% in Q2. The full-year goal tests whether that progress lasts.
Supportive ifEton reports an adjusted gross margin above 70% for full-year 2026.
Worry ifEton reports full-year 2026 adjusted gross margin at or below 70%.